Literature DB >> 7604879

Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma.

S N Wagner1, M J Atkinson, S Thanner, C Wagner, M Schmitt, O Wilhelm, M Rotter, H Höfler.   

Abstract

In vivo and in vitro experimental models have suggested a major role for the urokinase-type plasminogen activator (uPA) in tumor cell invasion and metastasis. The uPA proteolytic activity of tumor cells has been shown to be largely determined by the extent of the expression and saturation of the uPA receptor. We have analyzed the expression and cellular localization of both uPA and uPA receptor at the protein and mRNA levels in 33 paired samples of renal cell carcinoma (RCC) and non-tumorous kidney tissue. In comparison with adjacent normal non-tumorous kidney tissues RCC tumor cells modestly overexpressed uPA-receptor mRNA and showed significantly decreased uPA mRNA expression. However, the immunoreactive uPA content of tumor cells was comparable to that of the surrounding normal non-tumorous kidney tissue. Assuming constancy of the uPA-receptor affinity for uPA this indicates that a proportion of the RCC-associated uPA may be derived from an exogenous source and subsequently concentrated at the tumor cell surface via uPA receptor expression. The modest increase in uPA receptor expression may lead to a normalization of uPA antigen content in RCC; however, it is not sufficient to substantially increase tumor tissue-uPA content over the level of normal non-tumorous kidney tissue.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7604879      PMCID: PMC1869882     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  56 in total

1.  Decreased expression of the glutathione S-transferases alpha and pi genes in human renal cell carcinoma.

Authors:  A Klöne; U Weidner; R Hussnätter; J Harris; D Meyer; S Peter; B Ketterer; H Sies
Journal:  Carcinogenesis       Date:  1990-12       Impact factor: 4.944

Review 2.  Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.

Authors:  L A Liotta; P S Steeg; W G Stetler-Stevenson
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

3.  Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.

Authors:  M S Baker; P Bleakley; G C Woodrow; W F Doe
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

4.  Tissue cooperation in a proteolytic cascade activating human interstitial collagenase.

Authors:  C S HE; S M Wilhelm; A P Pentland; B L Marmer; G A Grant; A Z Eisen; G I Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

5.  Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells.

Authors:  J F Cajot; J Bamat; G E Bergonzelli; E K Kruithof; R L Medcalf; J Testuz; B Sordat
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

6.  Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.

Authors:  J Grøndahl-Hansen; E Ralfkiaer; L T Kirkeby; P Kristensen; L R Lund; K Danø
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

7.  Modulation of pro-epidermal growth factor, pro-transforming growth factor alpha and epidermal growth factor receptor gene expression in human renal carcinomas.

Authors:  P E Petrides; S Bock; J Bovens; R Hofmann; G Jakse
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

8.  Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma.

Authors:  U Weidner; S Peter; T Strohmeyer; R Hussnätter; R Ackermann; H Sies
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

9.  Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.

Authors:  A L Roldan; M V Cubellis; M T Masucci; N Behrendt; L R Lund; K Danø; E Appella; F Blasi
Journal:  EMBO J       Date:  1990-02       Impact factor: 11.598

10.  The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes.

Authors:  A Estreicher; J Mühlhauser; J L Carpentier; L Orci; J D Vassalli
Journal:  J Cell Biol       Date:  1990-08       Impact factor: 10.539

View more
  5 in total

1.  Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.

Authors:  T Luther; V Magdolen; S Albrecht; M Kasper; C Riemer; H Kessler; H Graeff; M Müller; M Schmitt
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

2.  Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.

Authors:  Kyung Hee Lee; Eun Young Choi; Myung Soo Hyun; Byung Ik Jang; Tae Nyeun Kim; Heon Ju Lee; Jong Yuel Eun; Hong Gin Kim; Sung Soo Yoon; Dong Sik Lee; Jung Hye Kim; Jae-Ryong Kim
Journal:  Clin Exp Metastasis       Date:  2007-11-09       Impact factor: 5.150

3.  Urokinase type plasminogen activator receptor expression in colorectal neoplasms.

Authors:  S Suzuki; Y Hayashi; Y Wang; T Nakamura; Y Morita; K Kawasaki; K Ohta; N Aoyama; S R Kim; H Itoh; Y Kuroda; W F Doe
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

4.  Cell surface antigens in renal tumour cells: detection by immunoluminescence and enzymatic analysis.

Authors:  F Laube; B Göhring; H Sann; I Willhardt
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

Review 5.  Characterization and function of human Ly-6/uPAR molecules.

Authors:  Hyun Kyung Kong; Jong Hoon Park
Journal:  BMB Rep       Date:  2012-11       Impact factor: 4.778

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.